Moreover, JQ-FT is 150-fold more tolerable in mice compared to unconjugated thapsigargin, without killing the antileukemic effect in a preclinical NOTCH1 mutated T-ALL model in vivo. Here, NOTCH1 is linked to acute lymphoblastic leukemia.